Market Overview

Puma Biotech Closes $138M Offering of Stock; 8.63M Shares at $16

Related PBYI
Puma Biotechnology to Hold Conference Call to Provide Update on PB272 Clinical Trials in Patients with HER2 Mutations
Benzinga's Top Initiations
Puma Bio prices stock offering at $40; shares down 7% premarket (Seeking Alpha)

Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced the closing of the underwritten public offering of 8,625,000 shares of its common stock at a price to the public of $16.00 per share. The shares of common stock issued in the offering included 1,125,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. The net proceeds from the offering were approximately $129.1 million, after deducting the underwriting discount and estimated offering expenses payable by the Company.

Posted-In: News Offerings


Related Articles (PBYI)

View Comments and Join the Discussion!